A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

NCT00152958 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Restless Legs Syndrome

Interventions

DRUG: Pramipexole

Sponsor

Boehringer Ingelheim